Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection

Clinical Microbiology and Infection

Volumn 20, Issue 12, 2014, Pages 1343-1351

  Varier, R U ^a,b   Biltaji, E ^c   Smith, K J ^d   Roberts, M S ^e   Jensen, M K ^a   Lafleur, J ^c   Nelson, R E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Northwest Gastroenterology Clinic   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Colonoscopy; Decision analysis; Enteric infection; Healthcare economics; Stool transplant

Indexed keywords

CLOSTRIDIUM DIFFICILE;

ANTIINFECTIVE AGENT; METRONIDAZOLE; VANCOMYCIN;

BIOLOGICAL THERAPY; CLOSTRIDIUM INFECTIONS; COMPARATIVE STUDY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; QUALITY ADJUSTED LIFE YEAR;

ANTI-BACTERIAL AGENTS; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; HUMANS; METRONIDAZOLE; QUALITY-ADJUSTED LIFE YEARS; VANCOMYCIN;

EID: 84920282075     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12805     Document Type: Article

References (57)

1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12: 409-415.
2. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13: 1417-1419.
3. Gravel D, Miller M, Simor A et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009; 48: 568-576.
4. Burckhardt F, Friedrich A, Beier D, Eckmanns T. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis 2008; 14: 691-692.
5. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-498- quiz 499.
6. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28: 1219-1227.
7. McGlone SM, Bailey RR, Zimmer SM et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2011; 18: 282-289.
8. McFarland LV. Emerging therapies for Clostridium difficile infections. Expert Opin Emerg Drugs 2011; 16: 425-439.
9. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-455.
10. O'Horo JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2014; 42: 43-59.
11. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-1775.
12. Leong C, Zelenitsky S. Treatment strategies for recurrent Clostridium difficile infection. Can J Hosp Pharm 2013; 66: 361-368.
13. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58: 403-410.
14. Bakken JS, Borody T, Brandt LJ et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-1049.
15. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-508.
16. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
17. Brandt LJ. American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 2013; 108: 177-185.
18. Brandt LJ, Aroniadis OC, Mellow M et al. Long-term follow-up of Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079-1087.
19. Agito MD, Atreja A, Rizk MK. Fecal microbiota transplantation for recurrent C difficile infection: ready for prime time? Clevel Clin J Med 2013; 80: 101-108.
20. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 2013; 78: 240-249.
21. Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol 2012; 5: 403-420.
22. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012; 35: 865-875.
23. Borody TJ, Campbell J. Fecal microbiota transplantation. Gastroenterol Clin North Am 2012; 41: 781-803.
24. Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014; 58: 1507-1514.
25. Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur J Clin Microbiol Infect Dis 2012; 31: 3163-3171.
26. McFarland LV, Surawicz CM, Rubin M et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20: 43-50.
27. Figueroa I, Johnson S, Sambol SP et al. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012; 55(Suppl 2): S104-S109.
28. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638-658.
29. Ko CW, Dominitz JA. Complications of colonoscopy: magnitude and management. Gastrointest Endosc Clin N Am 2010; 20: 659-671.
30. Consumer Price Index 2014. www.bls.gov/cpi/cpifiles/cpiai.txt. Accessed January 14, 2014.
31. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 96-104.
32. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An Economic Analysis Clin Infect Dis 2013; 57: 555-561.
33. Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013; 16: 297-304.
34. Constantinides VA, Heriot A, Remzi F et al. Operative strategies for diverticular peritonitis: a decision analysis between primary resection and anastomosis versus Hartmann's procedures. Ann Surg 2007; 245: 94-103.
35. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 2006; 21: 402-408.
36. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92: 739-750.
37. McFarland LV, Mulligan ME, Kwok R. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204-210.
38. Fujitani S, George WL, Murthy AR. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 2011; 32: 220-228.
39. Henrich TJ, Krakower D, Bitton A. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009; 15: 415-422.
40. Barbut F, Gariazzo B, Bonné L et al. Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. Infect Control Hosp Epidemiol 2007; 28: 131-139.
41. Sailhamer EA, Carson K, Chang Y et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009; 144: 433-439-discussion 439-440.
42. Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-372.
43. Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307.
44. Pepin J. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J 2004; 171: 466-472.
45. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38: 350-354.
46. McElligott KA, Havrilesky LJ, Myers ER. Preoperative screening strategies for bacterial vaginosis prior to elective hysterectomy: a cost comparison study. Am J Obstet Gynecol 2011; 205: 500.e1-500.e7.
47. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-1079.
48. Physician Fee Schedule - Search Results (CPT 45378). Centers for Medicare and Medicaid Services Website. http://www.cms.gov/apps/physician-fee-schedule/search/search-results.aspx?Y=3&T=0&HT=0&CT=3&H1=45378&M=5. Accessed January 14, 2014.
49. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50, 000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008; 8: 165-178.
50. Braithwaite RS, Meltzer DO, King JTJ, Leslie D, Roberts MS. What does the value of modern medicine say about the $50, 000 per quality-adjusted life-year decision rule? Med Care 2008; 46: 349-356.
51. Kunimoto D, Thomson AB. Recurrent Clostridium difficile-associated colitis responding to cholestyramine. Digestion 1986; 33: 225-228.
52. Yamazaki S, Nakamura H, Yamagata S et al. Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency. Int J Clin Pharmacol Ther 2009; 47: 701-706.
53. Quera R, Espinoza R, Estay C, Rivera D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. J Crohns Colitis 2014; 8: 252-253.
54. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11: 1036-1038.
55. Fecal transplant pill knocks out recurrent C. diff infection. Infectious Diseases Society of America "Fecal transplant pill knocks out recurrent C diff infection" ScienceDaily, 4 October 2013. www.sciencedaily.com/releases/2013/10/131004105253.htm. Accessed January 27, 2014.
56. Youngster I, Sauk J, Pindar C et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, Controlled Pilot Study. Clin Infect Dis 2014; 58: 1515-1522.
57. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-431.